Securities Announcement No.:
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332)
Special report on the deposit and actual use of raised funds in 2021
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
According to the guidelines for the supervision of listed companies No. 2 – regulatory requirements for the management and use of raised funds by listed companies (revised in 2022) (CSRC announcement [2022] No. 15) issued by the China Securities Regulatory Commission (“CSRC”) According to the relevant provisions of the self regulatory guidelines for listed companies on Shanghai Stock Exchange No. 1 – standardized operation and the self regulatory guidelines for listed companies on Shanghai Stock Exchange No. 1 – announcement format, Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) (“the company”, “the company” or ” Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) “) gives the following special instructions on the deposit and actual use of raised funds in 2021:
1、 Basic information of raised funds
(I) the actual amount of funds raised and the time of receipt of funds after deducting the issuance expenses
According to the resolutions of the 8th meeting of the 6th board of directors and the 13th meeting of the 6th board of directors of the company, and approved by the reply on approving Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) non-public development of shares issued by the CSRC (zjxk [2016] No. 826), the company non-public development of 334711699 ordinary shares (A shares), with a par value of 1.00 yuan per share (RMB, the same below), and an increase of 33471169900 yuan in share capital, The changed share capital is 162579094900 yuan. As of August 11, 2016, the company had issued 334711699 ordinary shares (A shares) in RMB through non-public offering, with an issue price of 23.56 yuan per share, and the total amount of funds raised was 788580762844 yuan. After deducting 2236110011 yuan of various issuance expenses, the net amount of funds actually raised was 786344652833 yuan. Among them, the newly increased share capital was 334711699 yuan and the increased capital reserve was 752873482933 yuan. The above raised funds have been verified by Lixin Certified Public Accountants (special general partnership) and issued a capital verification report (xksbz [2016] No. 410605).
(II) use amount and current balance of raised funds
As of December 31, 2021, the use of the raised funds of the company is as follows:
Amount of project raised funds
(10000 yuan)
Net proceeds 78634465
Less: accumulated expenditure of raised investment projects (including self owned capital investment in the early stage of replacement) 62214635
Including: accumulated expenditure before December 31, 2020: 52013465
Cumulative expenditure in 2021: 10201170
Less: bank service charge expenditure 30.83
Less: net purchase of principal guaranteed financial products with idle raised funds –
Plus: the accumulated interest income of special account and principal guaranteed financial products is 5382363
As of December 31, 2021, the balance of the special account for raised funds was 21799110
In 2021, the actual use of the raised funds by the company and its subordinate enterprises implementing the raised funds was 102017 million yuan; As of December 31, 2021, the total amount of raised funds invested has been 6221463500 yuan (including the investment of self owned funds in the early stage of replacement). For details, see attached table 1 comparison table of use of raised funds and attached table 2 table of change of investment projects of raised funds.
2、 Management of raised funds
In order to standardize the management and use of the company’s raised funds and protect the rights and interests of investors, the company formulated the measures for the management of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) raised funds (“measures for the management of raised funds”), which was deliberated and adopted by the company’s first extraordinary general meeting in 2015.
In accordance with the regulations of the regulatory authorities and the requirements of the measures for the management of raised funds, the company has established six special accounts for raised funds in Guangzhou Jincheng Branch of Shanghai Pudong Development Bank, Guangzhou Shamian branch of Guangdong Development Bank Co., Ltd. (“Shamian branch of Guangdong Development Bank”), China Everbright Bank Company Limited Co.Ltd(601818) Guangzhou Yangji branch (” China Everbright Bank Company Limited Co.Ltd(601818) Yangji branch”), China Citic Bank Corporation Limited(601998) Guangzhou Branch (” China Citic Bank Corporation Limited(601998) Guangzhou Branch”), On August 29, 2016, Huatai United Securities Co., Ltd. (“Huatai United Securities”) and the above-mentioned banks signed the tripartite supervision agreement on the storage of special accounts for raised funds.
In order to ensure the standardization of the management and use of the company’s raised funds and protect the rights and interests of investors, according to the provisions of relevant laws and regulations, Guangzhou wanglaojida Health Industry Co., Ltd. (“wanglaojida health company”), Guangzhou Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) Mingxing Pharmaceutical Co., Ltd. (“Mingxing pharmaceutical”) Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) he Jigong pharmaceutical factory (“he Jigong pharmaceutical factory”) has established special accounts for raised funds in China Everbright Bank Company Limited Co.Ltd(601818) Yangji sub branch and Shamian sub branch of Guangdong Development Bank, and signed the four party supervision agreement on the storage of special accounts for raised funds with Huatai United Securities, the company and the above-mentioned banks on January 24, 2017 Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) Pharmaceutical General Factory (” Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) Pharmaceutical General Factory”), Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) Guangzhou Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) chemical pharmaceutical factory (“chemical pharmaceutical factory”) and Guangzhou Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) Hanfang Modern Pharmaceutical Co., Ltd. (“Guangzhou Hanfang”) cooperated with Huatai United Securities, the company Guangzhou Branch of Shanghai Pudong Development Bank signed the four party supervision agreement on the storage of special account for raised funds; Guangzhou zezhilin Pharmaceutical Co., Ltd. (“zezhilin pharmaceutical”) signed the four party supervision agreement on the storage of special account for raised funds with Huatai United Securities, the company and China Citic Bank Corporation Limited(601998) Guangzhou Branch on September 11, 2019; Wanglaojida health Co., Ltd. changed the special account bank of raised funds for the “channel construction and brand construction” project from China Everbright Bank Company Limited Co.Ltd(601818) Yangji sub branch to the Development Zone sub branch of Bank of Guangzhou Co., Ltd. (“Development Zone sub branch of Bank of Guangzhou”) in January 2020, and signed the four party supervision agreement on the storage of special account of raised funds with Huatai United Securities, the company and the Development Zone sub branch of Bank of Guangzhou on February 25, 2020; Guangzhou Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) Baidi biomedical Co., Ltd. (“Guangzhou Baidi”), Mingxing pharmaceutical and Caizhilin pharmaceutical signed the four party supervision agreement on special account storage of raised funds with Huatai United Securities, the company and Guangzhou Branch of Shanghai Pudong Development Bank on May 7, 2020; Guangyao Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) Chemical Pharmaceutical (Zhuhai) Co., Ltd. signed the four party supervision agreement on the storage of special account for raised funds with Huatai United Securities Co., Ltd. and Guangzhou Branch of Shanghai Pudong Development Bank on January 8, 2021; On August 9, 2021, Guangzhou Pharmaceutical Research Institute Co., Ltd. (“Guangzhou Pharmaceutical Research Institute”) signed the four party supervision agreement on the storage of special account for raised funds with Huatai United Securities, the company and Guangzhou Branch of Shanghai Pudong Development Bank; Gansu Guangyao Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) traditional Chinese Medicine Technology Co., Ltd. signed the four party supervision agreement on the storage of special account for raised funds with Huatai United Securities, the company and Guangzhou Branch of Shanghai Pudong Development Bank on December 6, 2021.
As of December 31, 2021, the specific deposit of raised funds is as follows:
Account name deposit bank fund purpose bank account number / account balance usage status certificate of deposit category (10000 yuan)
Research on the development of “Great Southern medicine” in Pudong, Shanghai
The company’s Bank Guangzhou Jinfa platform construction 82090158 Ping An Bank Co.Ltd(000001) 37 current 10295172 normal use city sub branch project
Guangdong Development Bank Co., Ltd. “Da Nan Yao” student
Construction project of Zhoutan village sub branch for normal use of phase I 955088 Lijiang Yulong Tourism Co.Ltd(002033) 6100164 current 7660357 of Guangchan base of the company
(note)
Developing modern pharmaceutical logistics in Pudong, Shanghai
The company’s Bank Guangzhou Jin service extension item 82090158 Csg Holding Co.Ltd(000012) 9 current account – cancelled City sub branch
China China Everbright Bank Company Limited Co.Ltd(601818)
The company’s public channel construction and product 38670188 Xi’An Catering Co.Ltd(000721) 61 current 1215065 normal use division Guangzhou Yangji brand construction project
Sub branch
China Citic Bank Corporation Limited(601998) stock information platform construction
The company’s limited company wide establishment project 81109010130 Shenzhen Zhongzhuang Construction Group Co.Ltd(002822) 18 current – cancelled state branch
China Citic Bank Corporation Limited(601998) shares supplement working capital
The Company Limited Guangzhou Project 81109010124 Shenzhen Zhongzhuang Construction Group Co.Ltd(002822) 16 current 116305 normal use state branch
China China Everbright Bank Company Limited Co.Ltd(601818)
Wang Laoji Dajian Co., Ltd. public channel construction and product 3867018800074881 current – Guangzhou Yangji brand construction project of KangSi company has been cancelled
Sub branch
Wang Laoji Dajian Bank of Guangzhou stock channel construction and product
Licensing construction project of Kangkang Co., Ltd. 8 Shandong Ruyi Woolen Garment Group Co.Ltd(002193) 85702988 current – FA Qu sub branch cancelled
Guangdong Development Bank Co., Ltd. “Da Nan Yao” production
Mingxing Pharmaceutical Co., Ltd. Guangzhou base phase I construction 9550880204644500171 current 710793 normal use zhouqianjin sub branch project
(note)
Guangdong Development Bank Co., Ltd. “Da Nan Yao” production
He Jigong Pharmaceutical Factory Co., Ltd. Guangzhou base phase I construction 9550880204652 Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) current – cancelled zhoushamian sub branch project
Shanghai Pudong develops “Great Southern medicine” R & D
Research and development of chemical pharmaceutical factory Bank Guangzhou Jin platform construction project 820900788013 Ping An Bank Co.Ltd(000001) 89 current 850.04 normal use city sub branch
investment
Account name deposit bank fund purpose bank account number / account balance usage status certificate of deposit category (10000 yuan)
Shanghai Pudong develops “Great Southern medicine” R & D
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) pharmaceutical Bank Guangzhou Jinping platform construction project 820900788010 Ping An Bank Co.Ltd(000001) 81 current 570846 R & D in normal use General Factory City sub branch
investment
